Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Abstract 2587: A novel covalent inhibitor of mutant but not wild-type (WT) epidermal growth factor receptor (EGFR) has activity in vitro and in vivo in non-small cell lung cancer (NSCLC) models

Pedro J. Beltran, Jinghui Zhan, Petia Mitchell, Ryan P. Wurz, Liping Pettus, Tian Wu, Mary Chaves, Darren L. Reid, Robert Radinsky, Keegan Cooke, Andrew Tasker

Cancer Res (2015) 75 (15_Supplement): 2587.

https://doi.org/10.1158/1538-7445.AM2015-2587

Published: 01 August 2015

View articletitled, Abstract 2587: A novel covalent inhibitor of mutant but not wild-type (WT) epidermal growth factor receptor (EGFR) has activity in vitro and in vivo in non-small cell lung cancer (NSCLC) models

Journal Articles

Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models

Paul E. Hughes, Yajing Yang, Karen Rex, Yihong Zhang, Paula J. Kaplan-Lefko, Sean Caenepeel, Jodi Moriguchi, Martin Broome, Deborah Choquette, Robert Radinsky, Richard Kendall, Angela Coxon, Isabelle Dussault

Cancer Res (2014) 74 (19_Supplement): 728.

https://doi.org/10.1158/1538-7445.AM2014-728

Published: 01 October 2014

View articletitled, Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models

Journal Articles

Abstract 5089: Combined treatment of trebananib (AMG 386) with panitumumab in preclinical tumor models.

James V. Bready, Paula Kaplan-Lefko, Jodi Moriguchi, Marc Payton, Stephen Kaufman, Jonathan Oliner, Robert Radinsky, Angela Coxon

Cancer Res (2013) 73 (8_Supplement): 5089.

https://doi.org/10.1158/1538-7445.AM2013-5089

Published: 15 April 2013

View articletitled, Abstract 5089: Combined treatment of trebananib (AMG 386) with panitumumab in preclinical tumor models.

Journal Articles

Abstract 5158: Generation of a fully human Gas6 neutralizing antibody with anti-tumor activity in vivo.

Gordon E. Moody, Brian Belmontes, Chadwick King, Shuying Liu, Stephanie Masterman, Chris Murawsky, Trace Tsuruda, Wei Wang, Robert Radinsky, Pedro J. Beltran

Cancer Res (2013) 73 (8_Supplement): 5158.

https://doi.org/10.1158/1538-7445.AM2013-5158

Published: 15 April 2013

View articletitled, Abstract 5158: Generation of a fully human Gas6 neutralizing antibody with anti-tumor activity in vivo.

Journal Articles

Abstract 2805: In vitro characterization of AMG 511, a potent and selective class I PI3K inhibitor for the treatment of cancer

Sean Caenepeel, Nancy Zhang, Ling Wang, Mark H. Norman, Terri Burgess, Robert Radinsky, Rick Kendall, Daniel Freeman, Paul E. Hughes

Cancer Res (2012) 72 (8_Supplement): 2805.

https://doi.org/10.1158/1538-7445.AM2012-2805

Published: 15 April 2012

View articletitled, Abstract 2805: In vitro characterization of AMG 511, a potent and selective class I PI3K inhibitor for the treatment of cancer

Journal Articles

Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models

Nancy Zhang, Sean Caenepeel, Ling Wang, Mark Norman, Richard Kendall, Terri Burgess, Robert Radinsky, Paul Hughes, Daniel J. Freeman

Cancer Res (2012) 72 (8_Supplement): 2797.

https://doi.org/10.1158/1538-7445.AM2012-2797

Published: 15 April 2012

View articletitled, Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models

Journal Articles

Abstract 3556: Antitumor activity of AMG 900, an orally available small molecule inhibitor of aurora kinases, alone and in combination with tubulin-targeting agents in human metastatic breast cancer

Tammy L. Bush, Scott Heller, Grace Chung, Deborah Guyot, Richard Kendall, Greg Friberg, Robert Radinsky, Marc Payton

Cancer Res (2011) 71 (8_Supplement): 3556.

https://doi.org/10.1158/1538-7445.AM2011-3556

Published: 15 April 2011

View articletitled, Abstract 3556: Antitumor activity of AMG 900, an orally available small molecule inhibitor of aurora kinases, alone and in combination with tubulin-targeting agents in human metastatic breast cancer

Journal Articles

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

Cancer Res (2010) 70 (23): 9846–9854.

https://doi.org/10.1158/0008-5472.CAN-10-3001

Published: 06 December 2010

View articletitled, Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

Includes: Supplementary data

Journal Articles

Abstract 21: Selective and potent inhibitors of the mutant B-Raf pathway paradoxically stimulate the MAPK pathway in wild-type B-Raf cells

Josette Carnahan, Pedro Beltran, Carol Babij, Quynh Le, Mark J. Rose, Steven Vonderfecht, Joseph L. Kim, Adrian L. Smith, Martin A. Broome, Manory Fernando, Hue Kha, Brian Belmontes, Robert Radinsky, Richard Kendall, Teresa L. Burgess

Cancer Res (2010) 70 (8_Supplement): 21.

https://doi.org/10.1158/1538-7445.AM10-21

Published: 15 April 2010

View articletitled, Abstract 21: Selective and potent inhibitors of the mutant B-Raf pathway paradoxically stimulate the MAPK pathway in wild-type B-Raf cells

Journal Articles

Abstract LB-306: U3-1287 (AMG 888), a fully human anti-HER3 mAb, inhibits HER3 activation and induces HER3 internalization and degradation

Thore Hettmann, Matthias Schneider, Selam Ogbagabriel, Jiansong Xie, Gloria Juan, Susanne Hartmann, Robert Radinsky, Daniel J. Freeman

Cancer Res (2010) 70 (8_Supplement): LB-306.

https://doi.org/10.1158/1538-7445.AM10-LB-306

Published: 15 April 2010

View articletitled, Abstract LB-306: U3-1287 (AMG 888), a fully human anti-HER3 mAb, inhibits HER3 activation and induces HER3 internalization and degradation

Journal Articles

Abstract 5776: Discovery of AMG 900, a highly selective, orally bioavailable inhibitor of aurora kinases with efficacy in preclinical antitumor models and activity against multidrug-resistant cells

Cancer Res (2010) 70 (8_Supplement): 5776.

https://doi.org/10.1158/1538-7445.AM10-5776

Published: 15 April 2010

View articletitled, Abstract 5776: Discovery of AMG 900, a highly selective, orally bioavailable inhibitor of aurora kinases with efficacy in preclinical antitumor models and activity against multidrug-resistant cells

Journal Articles

Abstract 4437: Preclinical characterization of AMG 900, an orally available small molecule inhibitor of aurora kinases in phase 1 clinical trials

Tammy L. Bush, Grace Chung, Beth Ziegler, Patrick Eden, Patricia McElroy, Min-Hwa Jasmine Lin, Robert Radinsky, Richard Kendall, Stephanie Geuns-Meyer, Marc Payton

Cancer Res (2010) 70 (8_Supplement): 4437.

https://doi.org/10.1158/1538-7445.AM10-4437

Published: 15 April 2010

View articletitled, Abstract 4437: Preclinical characterization of AMG 900, an orally available small molecule inhibitor of aurora kinases in phase 1 clinical trials

Journal Articles

Abstract 3600: Preclinical pharmacokinetic and biomarker analysis of AMG 900, an orally available small molecule inhibitor of aurora kinases, in human xenograft tumor and surrogate tissues

Beth Ziegler, Gloria Juan, Grace Chung, Raffi Manoukian, Liyue Huang, Min-Hwa Jasmine Lin, Connie Ma, Stephen Zoog, Stephanie Geuns-Meyer, Richard Kendall, Robert Radinsky, Greg Friberg, Marc Payton, Tammy L. Bush

Cancer Res (2010) 70 (8_Supplement): 3600.

https://doi.org/10.1158/1538-7445.AM10-3600

Published: 15 April 2010

View articletitled, Abstract 3600: Preclinical pharmacokinetic and biomarker analysis of AMG 900, an orally available small molecule inhibitor of aurora kinases, in human xenograft tumor and surrogate tissues

Journal Articles

Abstract 2519: Efficacy of a potent and selective Raf inhibitor against human xenograft models displaying specific genetic mutations in the MAPK signaling pathway

Pedro J. Beltran, Josette Carnahan, Quynh Le, Manory Fernando, Mark J. Rose, Karthik Nagapudi, Adrian L. Smith, Joseph L. Kim, Brian Belmontes, Teresa L. Burgess, Richard Kendall, Robert Radinsky

Cancer Res (2010) 70 (8_Supplement): 2519.

https://doi.org/10.1158/1538-7445.AM10-2519

Published: 15 April 2010

View articletitled, Abstract 2519: Efficacy of a potent and selective Raf inhibitor against human xenograft models displaying specific genetic mutations in the MAPK signaling pathway

Journal Articles

Abstract #140: Assessment of angiogenesis inhibitors in the retinopathy of prematurity model in mice

Juan Estrada, Stephen Kaufman, Eunju Hurh, Daniel Freeman, Richard Kendall, Robert Radinsky, Anthony Polverino, Jonathan Oliner, Angela Coxon, James Bready

Cancer Res (2009) 69 (9_Supplement): 140.

Published: 01 May 2009

View articletitled, Abstract #140: Assessment of angiogenesis inhibitors in the retinopathy of prematurity model in mice

Journal Articles

Abstract #2805: AMG 479, a fully human anti-IGF-1R monoclonal antibody, inhibits rapamycin-induced Akt activation in sarcoma cell lines

Pedro Beltran, Young-Ah Chung, Petia Mitchell, Elaina Cajulis, Gordon Moody, Robert Radinsky, Frank Calzone

Cancer Res (2009) 69 (9_Supplement): 2805.

Published: 01 May 2009

View articletitled, Abstract #2805: AMG 479, a fully human anti-IGF-1R monoclonal antibody, inhibits rapamycin-induced Akt activation in sarcoma cell lines

Journal Articles

Modulation of radiation response by motesanib diphosphate in models of head and neck squamous cell carcinoma

Tim Kruser, Deric Wheeler, Shyhmin Huang, Eric Armstrong, Angela Coxon, Charlie Starnes, Tony Polverino, Robert Radinsky, Paul Harari

Cancer Res (2008) 68 (9_Supplement): 5764.

Published: 01 May 2008

View articletitled, Modulation of radiation response by motesanib diphosphate in models of head and neck squamous cell carcinoma

Journal Articles

Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors

Daniel Freeman, Selam Ogbagabriel, Mike Rothe, Robert Radinsky, Martin Treder

Cancer Res (2008) 68 (9_Supplement): LB-21.

Published: 01 May 2008

View articletitled, Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors

Journal Articles

Positron emission tomography (PET) measurement of death receptor 5 (DR5) receptor occupancy (RO) using ⁶⁴Cu-labeled AMG 655 in Colo205 xenografts

Dah-Ren Hwang, Raffaella Rossin, Brian Gliniak, Hiko Kohno, Thomas Arroll, Paula Kaplan-Lefko, Jeffery Wiezorek, Greg Friberg, Robert Radinsky, Jeffrey Evelhoch, Michael Welch

Cancer Res (2008) 68 (9_Supplement): 3162.

Published: 01 May 2008

View articletitled, Positron emission tomography (PET) measurement of death receptor 5 (DR5) receptor occupancy (RO) using 64Cu-labeled AMG 655 in Colo205 xenografts

Journal Articles

Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo

Martin Treder, Susanne Hartmann, Selam Ogbagabriel, Eric Borges, Larry Green, Jasal Kang, Robert Radinsky, Mike Rothe, Dan Freeman

Cancer Res (2008) 68 (9_Supplement): LB-20.

Published: 01 May 2008

View articletitled, Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 2587: A novel covalent inhibitor of mutant but not wild-type (WT) epidermal growth factor receptor (EGFR) has activity in vitro and in vivo in non-small cell lung cancer (NSCLC) models

Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models

Abstract 5089: Combined treatment of trebananib (AMG 386) with panitumumab in preclinical tumor models.

Abstract 5158: Generation of a fully human Gas6 neutralizing antibody with anti-tumor activity in vivo.

Abstract 2805: In vitro characterization of AMG 511, a potent and selective class I PI3K inhibitor for the treatment of cancer

Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models

Abstract 3556: Antitumor activity of AMG 900, an orally available small molecule inhibitor of aurora kinases, alone and in combination with tubulin-targeting agents in human metastatic breast cancer

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

Abstract 21: Selective and potent inhibitors of the mutant B-Raf pathway paradoxically stimulate the MAPK pathway in wild-type B-Raf cells

Abstract LB-306: U3-1287 (AMG 888), a fully human anti-HER3 mAb, inhibits HER3 activation and induces HER3 internalization and degradation

Abstract 5776: Discovery of AMG 900, a highly selective, orally bioavailable inhibitor of aurora kinases with efficacy in preclinical antitumor models and activity against multidrug-resistant cells

Abstract 4437: Preclinical characterization of AMG 900, an orally available small molecule inhibitor of aurora kinases in phase 1 clinical trials

Abstract 3600: Preclinical pharmacokinetic and biomarker analysis of AMG 900, an orally available small molecule inhibitor of aurora kinases, in human xenograft tumor and surrogate tissues

Abstract 2519: Efficacy of a potent and selective Raf inhibitor against human xenograft models displaying specific genetic mutations in the MAPK signaling pathway

Abstract #140: Assessment of angiogenesis inhibitors in the retinopathy of prematurity model in mice

Abstract #2805: AMG 479, a fully human anti-IGF-1R monoclonal antibody, inhibits rapamycin-induced Akt activation in sarcoma cell lines

Modulation of radiation response by motesanib diphosphate in models of head and neck squamous cell carcinoma

Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors

Positron emission tomography (PET) measurement of death receptor 5 (DR5) receptor occupancy (RO) using ⁶⁴Cu-labeled AMG 655 in Colo205 xenografts

Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only